LEO 22811-S22 Proof of Concept Study (Phase II)
· Published by Health Canada · Official notice
Alert type: Drug Recall
Category: Drugs
Issue: Product Safety, Quality
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type III
| Lot or serial number | Common name | Companies | Dosage form | DIN, NPN, DIN-HIM | Strength |
|---|
| Bulk Batch No. 09 302 72 01 | LEO 22811-S22 Proof of Concept Study (Phase II) | - Recalling Firm
- LEO Pharma 123 Commerce Valley Drive East, Suite 400, Thornhill, Ontario L3T 7W8
- Marketing Authorization Holder
- N/A
- Recalling Firm
- LEO Pharma
| Oral Solution | N/A -Clinical Trial (IMP) | 0.0625 mg/mL of LEO 22811 |
Recalled products
-
LEO 22811-S22 Proof of Concept Study (Phase II)
Broken bottles and loose caps have been identified. A significant part of the bottles with loose caps are leaking.
The IMP has been distributed to six clinical sites in France, four clinical sites in Canada as well as one central depot in both France and Canada.